Plastic Surgery for Gynecomastia

Plastic Surgery for Gynecomastia

No Results

No Results


Gynecomastia is derived from the Greek terms gynec (feminine) and mastos (breast). The literal translation, male breasts, relates to any condition that results in excessive development of breast tissue in males. Males may rarely develop breast cancer, but this is often associated with testicular atrophy. [1]

Male breast volume is composed of a combination of ductal and stromal tissue, commonly referred to as glandular tissue, and an increase in adipocytes, typically referred to as fatty tissue. Excess skin resulting in significant ptosis of the breast may be present in patients with severe gynecomastia. See the images below.

Galen introduced the term gynecomastia in the second century AD. He defined gynecomastia as an unnatural increase in the breast fat of males. Although Galen was aware that glandular enlargement of the male breast occurred as a separate entity, he did not consider this gynecomastia.

The first recorded description of a reduction mammaplasty was by Paulas of Aegina in the seventh century AD, who referred to the condition as an “effeminacy of men.” Several medical and surgical treatments of gynecomastia were described in the 1800s.

Treatment of gynecomastia has continued to evolve over the ages. Presently, a multifaceted surgical approach is used to optimize correction of the deformity. The fatty component is removed with one or a combination of the variants of liposuction, while the glandular component requires direct excision. The skin is redraped over the underlying structures or, in severe cases, resected. The patient’s treatment plan should be crafted to correct the specific problems that are unique to his specific case. [2, 3, 4]

Gynecomastia results in an increase in breast tissue in males that, when problematic, is readily detectable by other individuals. The increased tissue may be breast glandular tissue, adipose (fatty) in nature, or a combination of the two. This results in significant functional and psychological limitations. The physical deformation may also be exquisitely painful. As a general rule, the glandular tissue is significantly more painful than the fatty tissue. Situations like gym class may require children or adolescents to remove their shirts in the presence of other students. This can put a boy with gynecomastia in danger not only of embarrassment but also of physical harm.

Most patients have never heard of this condition until the family physician identifies it. The physician may be unaware of the possible causes of the condition and its psychological impact. After initial presentation, boys are frequently advised to ignore the gynecomastia and are told that it will go away. Fortunately, in most instances, cases of minimal subareolar pubertal-onset gynecomastia do regress as puberty progresses.

Individuals with no regression or even progression of the deformity often receive little or no understanding about the shame and humiliation they experience. Coaches, sergeants, physicians, parents, and peers (both boys and girls) can inflict damage out of ignorance, cruelty, or both. The author reports that a parent recently exclaimed during an initial evaluation, “I just don’t understand why ‘he’ has to slouch around all the time.” Postural and clothing modifications to mask the deformity are the norm in these patients from puberty through adulthood.

Awareness of gynecomastia needs to progress in order to inform the men and boys with gynecomastia and their physicians what can be done to improve the condition.

Gynecomastia can occur in persons of any age. During adolescence, males develop firmness around the breast as the breast bud enlarges due to the hormonal fluxes of puberty. The subareolar firmness which normally develops regresses with time. Breast tissue is typically present on a microscopic level in male patients; a small amount of breast tissue is normal. The visible appearance of breast tissue in a male is abnormal.

The definition of clinically significant gynecomastia is subject to interpretation by any author; therefore, reports in the literature are often confusing, as the reader is forced to compare apples to oranges when examining different studies. Nydick et al reported 65% of boys “may have the problem” but cautioned that it typically resolves. [5] Webster noted the incidence of gynecomastia to be around 8% in a series of naval patients, [6] while Williams noted that 40% of men examined in his series of autopsies had gynecomastia to some degree. [7] Approximately 40% of healthy men and up to 70% of hospitalized men have palpable if not visible breast tissue. The incidence of some degree of palpable breast tissue in males increases to more than 60% in those in the seventh decade of life in one series.

Gynecomastia can be classified based on etiology. Idiopathic gynecomastia accounts for over 85% of cases that require surgical intervention.

Physiologic gynecomastia occurs primarily in newborns and in adolescents at puberty. In the newborn, the neonatal breast results from the action of maternal estrogens, placental estrogens, or both in concert. The increased breast tissue usually disappears in a few weeks. Neonatal gynecomastia is not a problem that requires surgical intervention.

Adolescent gynecomastia, by definition, is initiated during puberty. The median age of onset is 13 years. Breast tissue growth is often asymmetrical, and the breasts are frequently tender. Adolescent gynecomastia usually regresses by the latter teen years. Note that the normal course during puberty is for a palpable, often visible, mass below the areola that begins to resolve in the mid teen years. While continued visible enlargement in the size of the breast is not normal in a teenager, residual palpable gynecomastia may be present in one or both breasts through the mid teen years. The authors would stress that the norm would be progressive diminution of any visible or palpable deformity through this period. In each case, the clinician must evaluate the degree of tissue present, the clinical presentation, and the physical and psychological effects on the patient.

Pathologic gynecomastia may be due to testosterone deficiency, increased estrogen production, or increased conversion of androgens to estrogens. The pathological conditions associated with gynecomastia include congenital anorchia, Klinefelter syndrome, [8] testicular feminization, hermaphroditism, adrenal tumors, liver disorders, pituitary tumors, and malnutrition.

Many pharmacological agents have been linked to gynecomastia. [9] These drugs can be categorized by their mechanisms of action. The first type is drugs that act exactly like estrogens (eg, diethylstilbestrol, birth control pills, digitalis, estrogen-containing cosmetics). The second type is drugs that enhance endogenous estrogen formation (eg, gonadotropins, progesterone, clomiphene). The third type is drugs that inhibit testosterone synthesis and action (eg, ketoconazole, metronidazole, and cimetidine). The final type is drugs that act by unknown mechanisms (eg, isoniazid, [10] methyldopa, captopril, tricyclic antidepressants, diazepam, marijuana, heroin). While heavy marijuana use has been linked to gynecomastia in rats, the relationship in humans is at best poorly documented. Chronic alcohol abuse may result in hepatocellular destruction and scarring which may result in gynecomastia. Adult patients should be routinely questioned about alcohol abuse or addiction.

A link between testicular atrophy, Klinefelter syndrome, and breast cancer has been noted. Longstanding, stable gynecomastia in an otherwise healthy male does not require an extensive medical workup.

In boys, the main sex hormone is testosterone, which is secreted by the testes. In girls, the main sex hormone is estrogen, which is secreted by the ovaries. However, both hormones are secreted in both sexes. Some production of estrogen occurs in the testes, and some production of testosterone occurs in the ovaries. Gynecomastia has long been considered the result of an imbalance between estrogens, which stimulate breast tissue, and androgens, which antagonize this effect. An alteration in the normal ratio of estrogen to androgen has been found in patients with gynecomastia in association with many different etiological factors. [11, 12]

Estradiol is the growth hormone of the breast in women, and an excess of estradiol leads to the proliferation of breast tissue. Under normal circumstances, most estradiol in men is derived from the peripheral conversion of testosterone and adrenal estrogen. The basic mechanisms of physiologic gynecomastia have been postulated to represent a decrease in androgen production, an absolute increase in estrogen production, and an increased availability of estrogen precursors for peripheral conversion to estradiol. See the image below.

The etiology of most cases of gynecomastia remains unknown. The number of breast malignancies does not appear to be increased in patients with idiopathic gynecomastia. Patients who present with gynecomastia and have Klinefelter syndrome do exhibit an increased incidence of breast malignancies. Pensler et al noted that patients with Klinefelter syndrome exhibited elevated estrogen and progesterone receptors in their breast tissue. [13] The presence of elevated estrogen and progesterone receptors in patients with Klinefelter syndrome provides a potential mechanism by which these patients may develop breast neoplasms. By contrast, patients with idiopathic gynecomastia did not demonstrate an increased number of estrogen or progesterone receptors. Also, the binding affinity of the receptors in both groups were not affected. The absence of elevated progesterone or estrogen receptors in patients with idiopathic gynecomastia helps to explain why these patients rarely manifest breast malignancy.

Patients present with an increase in breast tissue, which is asymmetric in one third of cases. The degree of asymmetry between the two sides varies widely. [14] Some patients present with unilateral gynecomastia, while other individuals have a size discrepancy between the two sides that ranges from moderate to severe. Breast tenderness may also be noted in one third of patients. Enlargement is usually central and symmetric, although occasionally it is eccentric.

In 1934, Webster classified gynecomastia into 3 types. [6] The first is glandular. Patients with a glandular component require surgical removal of the gland. The second is fatty glandular. With the fatty glandular form, surgery combined with liposuction allows good contouring. The third is simple fatty. In the cases that are primarily fatty in nature, liposuction alone provides good results.

Another classification described by Simon in 1973 groups the patients into categories according to the size of the gynecomastia. [15] Group 1 is minor but visible breast enlargement without skin redundancy. Group 2A is moderate breast enlargement without skin redundancy. Group 2B is moderate breast enlargement with minor skin redundancy. Group 3 is gross breast enlargement with skin redundancy that simulates a pendulous female breast. Patients in groups 1 and 2 require no skin excision, but the breast development associated with group 3 is so marked that excess skin must be removed.

Generally, gynecomastia is a benign condition. Longstanding cases do not require histologic examination of surgically removed tissue. Rapid changes in the size of the breast, especially when unilateral in nature, may represent a malignancy particularly when pharmacologic manipulation can be ruled out. Also, changes in breast size in a patient with Klinefelter syndrome should be viewed with caution.

Surgical intervention is indicated in patients for diagnostic purposes or, most commonly, for patients who request treatment for physical modification. Most patients who visit a plastic surgeon request treatment for improvement of the obvious physical deformity which enhances psychological and physical well-being. These patients seek treatment because they find that the condition, which is readily apparent in everyday life, adversely impacts day-to-day activities under various circumstances. The physical deformation necessitates behavioral modifications that have numerous implications in the lives of the patients who are affected. Patients wear loose clothing and often avoid exposure in showers and swimming pools. Patients in high school and college are reticent to participate in any athletic activity that may directly or inadvertently require removal of one’s shirt, exposing the chest.

Patients with gynecomastia typically slouch forward and roll the shoulders toward the midline in an effort to camouflage the deformation. The aforementioned posturing has a submissive connotation to the public with whom they interact. Patients return for postoperative appointments standing tall. In cases involving teenagers, parents typically remark “I have been trying to have him stand up straight for years!” The postural changes alone, which result at all age levels both sitting and standing, have numerous positive implications in peer-to-peer interactions. The confidence a patient gains after surgery becomes a life-changing event.

A study by Innocenti et al suggested that the reason patients undergo gynecomastia surgery and their level of satisfaction with the operation vary with body type. The report involved adult patients classified according to one of three different body types—high muscle mass, normal, or overweight—who were treated with subcutaneous mastectomy. The investigators found that the primary reason patients with normal body type underwent surgery was emotional distress owing to a feminine chest appearance. In contrast, most of those with high muscle mass wanted the operation because unsatisfactory contouring of the pectoralis area had damaged their self-confidence, while the majority of patients in the overweight group underwent surgery because they looked upon gynecomastia as a weight disorder. The study also found that patients with normal body type had higher levels of satisfaction with their surgical outcomes than did members of the other two groups. [16]

The plastic surgeon must be familiar with the anatomy of the breast and be able to differentiate between the fat (adipose) tissue and the glandular tissue. In a liposuction-assisted mastectomy, the surgeon primarily targets the fatty component of the breast. The glandular tissue is quite dense and is extremely resistant to removal by any method other than direct excision. All patients have a glandular component and a fatty component. The requirement of direct surgical resection of glandular tissue in patients may explain the poor results obtained by some inexperienced practitioners in specific cases. As previously mentioned, longstanding stable cases of gynecomastia do not routinely require histological examination of the excised tissue.

See the images below.

Liposuction-assisted mastectomy with or without gland excision for gynecomastia patients can be performed under local anesthesia, intravenous conscious sedation, or general anesthesia. The choice of sedation should be determined preoperatively by the physician and patient. Any significant medical problems, such as heart disease, lung disease, or diabetes, must be excluded before the procedure is performed. Rapid or unusual progression or presentation of the disease may require endocrinologic evaluation, which is optimally preformed prior to any surgical intervention. If the etiology of the gynecomastia is related to an adrenal or pituitary tumor, the tumor should be addressed prior to any attempt to correct the gynecomastia. If the gynecomastia is related to drug use, the use of the offending agent should be stopped prior to surgery.

Males who are upset with the appearance of their chest may also have substantial psychological issues. A boy who is being abused or humiliated commonly focuses on some part of his external appearance to avoid dealing with internal pain that he feels unable to manage or control. What may have started as a minor physical condition can be a cover for much deeper emotional issues that no amount of surgery can resolve. While Yost has demonstrated that more than 91% of individuals who have had surgery are happy with the procedure and would recommend surgery to a friend, individuals who require multiple surgeries may need to be screened for body dysmorphic disorder (BDD) and referred for treatment. [17]

Vandeven HA, Pensler JM. Gynecomastia. 2018 Jan. [Medline]. [Full Text].

Devalia HL, Layer GT. Current concepts in gynaecomastia. Surgeon. 2009 Apr. 7(2):114-9. [Medline].

Abdelrahman I, Steinvall I, Mossaad B, Sjoberg F, Elmasry M. Evaluation of Glandular Liposculpture as a Single Treatment for Grades I and II Gynaecomastia. Aesthetic Plast Surg. 2018 Mar 16. [Medline].

Bellini E, Grieco MP, Raposio E. A journey through liposuction and liposculture: Review. Ann Med Surg (Lond). 2017 Dec. 24:53-60. [Medline]. [Full Text].

Nydick M, Bustos J, Dale JH Jr, Rawson RW. Gynecomastia in adolescent boys. JAMA. 1961 Nov 4. 178:449-54. [Medline].

Webster GV. Gynecomastia in the Navy. Mil Surg. 1944. 95:375-9.

Williams GM. Gynecomastia. N Engl J Med. 1993 Jul 15. 329(3):209. [Medline].

Los E, Ford GA. Klinefelter Syndrome. 2018 Jan. [Medline]. [Full Text].

Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf. 2008 Nov. 7(6):691-702. [Medline].

Morrone N, Morrone Junior N, Braz AG, Maia JA. Gynecomastia: a rare adverse effect of isoniazid. J Bras Pneumol. 2008 Nov. 34(11):978-81. [Medline].

Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism. 1986 Aug. 35(8):705-8. [Medline].

Parker S. A male breast lesion. [online]. Available at: January 2, 2003. [Full Text].

Pensler JM, Silverman BL, Sanghavi J, et al. Estrogen and progesterone receptors in gynecomastia. Plast Reconstr Surg. 2000 Oct. 106 (5):1011-3. [Medline].

Lee SR, Lee SG, Byun GY, Kim MJ, Koo BH. Clinical Characteristics of Asymmetric Bilateral Gynecomastia: Suggestion of Desirable Surgical Method Based on a Single-Institution Experience. Aesthetic Plast Surg. 2018 Jun. 42 (3):708-15. [Medline].

Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. Plast Reconstr Surg. 1973 Jan. 51(1):48-52. [Medline].

Innocenti A, Melita D, Mori F, Ciancio F, Innocenti M. Management of Gynecomastia in Patients With Different Body Types: Considerations on 312 Consecutive Treated Cases. Ann Plast Surg. 2017 May. 78 (5):492-6. [Medline]. [Full Text].

Yost, M. Demystifying Gynecomastia: Men with Breasts. ISBN 0-9777199-0-1: Mens Health; 2006. Vol 1: 1-122.

Singer-Granick CJ, Granick MS. Gynecomastia what the surgeon needs to know. Eplasty. 2009. 9:e6. [Medline]. [Full Text].

Athwal RK, Donovan R, Mirza M. Clinical examination allied to ultrasonography in the assessment of new onset gynaecomastia: an observational study. J Clin Diagn Res. 2014 Jun. 8 (6):NC09-11. [Medline]. [Full Text].

Fricke A, Lehner GM, Stark GB, Penna V. Gynecomastia: histological appearance in different age groups. J Plast Surg Hand Surg. 2018 Jun. 52 (3):166-71. [Medline].

Akgul S, Derman O, Kanbur N. The effect of tamoxifen on pubertal bone development in adolescents with pubertal gynecomastia. J Pediatr Endocrinol Metab. 2016 Jan 1. 29 (1):77-83. [Medline].

Hammond DC, Arnold JF, Simon AM, Capraro PA. Combined use of ultrasonic liposuction with the pull-through technique for the treatment of gynecomastia. Plast Reconstr Surg. 2003 Sep. 112(3):891-5; discussion 896-7. [Medline].

Bracaglia R, Fortunato R, Gentileschi S, Seccia A, Farallo E. Our experience with the so-called pull-through technique combined with liposuction for management of gynecomastia. Ann Plast Surg. 2004 Jul. 53(1):22-6. [Medline].

Lista F, Ahmad J. Power-assisted liposuction and the pull-through technique for the treatment of gynecomastia. Plast Reconstr Surg. 2008 Mar. 121(3):740-7. [Medline].

Teimourian B, Perlman R. Surgery for gynecomastia. Aesthetic Plast Surg. 1983. 7(3):155-7. [Medline].

Zavlin D, Jubbal KT, Friedman JD, Echo A. Complications and Outcomes After Gynecomastia Surgery: Analysis of 204 Pediatric and 1583 Adult Cases from a National Multi-center Database. Aesthetic Plast Surg. 2017 Aug. 41 (4):761-7. [Medline].

Kasielska-Trojan A, Danilewicz M, Antoszewski B. Is There a Rationale behind Pharmacotherapy in Idiopathic Gynecomastia?. Horm Res Paediatr. 2018 May 17. 1-5. [Medline].

Jay M Pensler, MD Aesthetic Plastic and Reconstructive Surgery, Private Practice; Clinical Associate Professor, Department of Surgery, Division of Plastic Surgery, Northwestern University, The Feinberg School of Medicine

Jay M Pensler, MD is a member of the following medical societies: American Academy of Pediatrics, American Burn Association, American Cleft Palate-Craniofacial Association, American College of Surgeons, American Medical Association, American Society for Aesthetic Plastic Surgery, American Society for Laser Medicine and Surgery, American Society of Maxillofacial Surgeons, American Society of Plastic Surgeons, Chicago Medical Society, Illinois State Medical Society, International College of Surgeons, Sigma Xi

Disclosure: Nothing to disclose.

Miguel A Delgado, Jr, MD, FACS Private Practice

Miguel A Delgado, Jr, MD, FACS is a member of the following medical societies: American Medical Association, American Society for Aesthetic Plastic Surgery, American Society of Plastic Surgeons, International Society of Hair Restoration Surgery

Disclosure: Nothing to disclose.

Merle J Yost, MA, LMFT Licensed Marriage and Family Therapist

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

James Neal Long, MD, FACS Founder of Magnolia Plastic Surgery; Former Associate Professor of Plastic and Reconstructive Surgery, Division of Plastic Surgery, Children’s Hospital and Kirklin Clinics, University of Alabama at Birmingham School of Medicine; Section Chief of Plastic, Reconstructive, Hand, and Microsurgery, Birmingham Veterans Affairs Medical Center

James Neal Long, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Medical Association, American Society of Plastic Surgeons, Plastic Surgery Research Council, Sigma Xi, Southeastern Society of Plastic and Reconstructive Surgeons, Southeastern Surgical Congress

Disclosure: Nothing to disclose.

Pankaj Tiwari, MD Assistant Professor, Division of Plastic Surgery, Ohio State University College of Medicine

Disclosure: Nothing to disclose.

Plastic Surgery for Gynecomastia

Research & References of Plastic Surgery for Gynecomastia|A&C Accounting And Tax Services